vs

Side-by-side financial comparison of Primis Financial Corp. (FRST) and PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB). Click either name above to swap in a different company.

Primis Financial Corp. is the larger business by last-quarter revenue ($45.6M vs $44.6M, roughly 1.0× PACIFIC BIOSCIENCES OF CALIFORNIA, INC.). Primis Financial Corp. runs the higher net margin — 16.0% vs -90.4%, a 106.5% gap on every dollar of revenue. Over the past eight quarters, Primis Financial Corp.'s revenue compounded faster (13.0% CAGR vs 7.3%).

Primis Financial Corp is a U.S.-based financial holding company operating full-service banking subsidiaries. It provides a comprehensive range of financial solutions including personal and commercial deposit products, diverse loan facilities, mortgage services, and wealth management support, primarily serving retail and corporate customers across the U.S. mid-Atlantic region.

Pacific Biosciences of California, Inc. is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. PacBio has two principal sequencing platforms: single-molecule real-time sequencing (SMRT), based on the properties of zero-mode waveguides and sequencing by binding (SBB) chemistry, which uses native nucleotides and scarless incorporation for DNA binding and extension.

FRST vs PACB — Head-to-Head

Bigger by revenue
FRST
FRST
1.0× larger
FRST
$45.6M
$44.6M
PACB
Higher net margin
FRST
FRST
106.5% more per $
FRST
16.0%
-90.4%
PACB
Faster 2-yr revenue CAGR
FRST
FRST
Annualised
FRST
13.0%
7.3%
PACB

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
FRST
FRST
PACB
PACB
Revenue
$45.6M
$44.6M
Net Profit
$7.3M
$-40.4M
Gross Margin
37.1%
Operating Margin
-92.3%
Net Margin
16.0%
-90.4%
Revenue YoY
13.8%
Net Profit YoY
200.0%
-1802.7%
EPS (diluted)
$0.30
$-0.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FRST
FRST
PACB
PACB
Q1 26
$45.6M
Q4 25
$80.9M
$44.6M
Q3 25
$41.0M
$38.4M
Q2 25
$43.2M
$39.8M
Q1 25
$58.7M
$37.2M
Q4 24
$38.8M
$39.2M
Q3 24
$37.3M
$40.0M
Q2 24
$35.7M
$36.0M
Net Profit
FRST
FRST
PACB
PACB
Q1 26
$7.3M
Q4 25
$29.5M
$-40.4M
Q3 25
$6.8M
$-38.0M
Q2 25
$2.4M
$-41.9M
Q1 25
$22.6M
$-426.1M
Q4 24
$-26.2M
$2.4M
Q3 24
$1.2M
$-60.7M
Q2 24
$3.4M
$-173.3M
Gross Margin
FRST
FRST
PACB
PACB
Q1 26
Q4 25
37.1%
Q3 25
41.4%
Q2 25
36.9%
Q1 25
-3.7%
Q4 24
25.6%
Q3 24
25.0%
Q2 24
16.5%
Operating Margin
FRST
FRST
PACB
PACB
Q1 26
Q4 25
44.8%
-92.3%
Q3 25
21.3%
-101.1%
Q2 25
6.9%
-112.8%
Q1 25
41.9%
-1154.5%
Q4 24
-123.0%
-390.1%
Q3 24
-3.1%
-160.3%
Q2 24
7.8%
-488.3%
Net Margin
FRST
FRST
PACB
PACB
Q1 26
16.0%
Q4 25
36.5%
-90.4%
Q3 25
16.7%
-98.9%
Q2 25
5.6%
-105.4%
Q1 25
38.6%
-1146.8%
Q4 24
-100.3%
6.0%
Q3 24
3.3%
-151.9%
Q2 24
9.6%
-481.3%
EPS (diluted)
FRST
FRST
PACB
PACB
Q1 26
$0.30
Q4 25
$1.19
$-0.11
Q3 25
$0.28
$-0.13
Q2 25
$0.10
$-0.14
Q1 25
$0.92
$-1.44
Q4 24
$-0.95
$-0.44
Q3 24
$0.05
$-0.22
Q2 24
$0.14
$-0.64

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FRST
FRST
PACB
PACB
Cash + ST InvestmentsLiquidity on hand
$159.9M
$279.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$427.2M
$5.3M
Total Assets
$4.3B
$784.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FRST
FRST
PACB
PACB
Q1 26
$159.9M
Q4 25
$143.6M
$279.5M
Q3 25
$63.9M
$298.7M
Q2 25
$94.1M
$314.7M
Q1 25
$57.0M
$343.1M
Q4 24
$64.5M
$389.9M
Q3 24
$77.3M
$471.1M
Q2 24
$66.6M
$509.8M
Stockholders' Equity
FRST
FRST
PACB
PACB
Q1 26
$427.2M
Q4 25
$422.9M
$5.3M
Q3 25
$382.2M
$36.1M
Q2 25
$376.4M
$61.5M
Q1 25
$375.6M
$91.6M
Q4 24
$351.8M
$506.6M
Q3 24
$381.0M
$453.1M
Q2 24
$376.0M
$492.7M
Total Assets
FRST
FRST
PACB
PACB
Q1 26
$4.3B
Q4 25
$4.0B
$784.1M
Q3 25
$4.0B
$803.2M
Q2 25
$3.9B
$825.5M
Q1 25
$3.7B
$860.8M
Q4 24
$3.7B
$1.3B
Q3 24
$4.0B
$1.5B
Q2 24
$4.0B
$1.5B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FRST
FRST
PACB
PACB
Operating Cash FlowLast quarter
$-19.1M
Free Cash FlowOCF − Capex
$-19.9M
FCF MarginFCF / Revenue
-44.6%
Capex IntensityCapex / Revenue
1.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-114.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FRST
FRST
PACB
PACB
Q1 26
Q4 25
$10.8M
$-19.1M
Q3 25
$-11.4M
$-18.7M
Q2 25
$-41.0M
$-29.4M
Q1 25
$34.4M
$-44.1M
Q4 24
$19.5M
$-30.6M
Q3 24
$6.1M
$-45.5M
Q2 24
$52.3M
$-54.3M
Free Cash Flow
FRST
FRST
PACB
PACB
Q1 26
Q4 25
$9.0M
$-19.9M
Q3 25
$-18.8M
Q2 25
$-29.9M
Q1 25
$-45.4M
Q4 24
$18.3M
$-32.3M
Q3 24
$-46.3M
Q2 24
$-55.7M
FCF Margin
FRST
FRST
PACB
PACB
Q1 26
Q4 25
11.2%
-44.6%
Q3 25
-48.9%
Q2 25
-75.3%
Q1 25
-122.3%
Q4 24
47.3%
-82.3%
Q3 24
-115.7%
Q2 24
-154.8%
Capex Intensity
FRST
FRST
PACB
PACB
Q1 26
Q4 25
2.1%
1.9%
Q3 25
0.2%
Q2 25
1.4%
Q1 25
3.7%
Q4 24
3.1%
4.1%
Q3 24
0.0%
2.0%
Q2 24
0.0%
4.1%
Cash Conversion
FRST
FRST
PACB
PACB
Q1 26
Q4 25
0.36×
Q3 25
-1.67×
Q2 25
-16.82×
Q1 25
1.52×
Q4 24
-12.93×
Q3 24
4.93×
Q2 24
15.21×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FRST
FRST

Net Interest Income$32.1M70%
Noninterest Income$13.6M30%

PACB
PACB

Products$39.0M87%
Service And Other$5.7M13%

Related Comparisons